Carl Zeiss Meditec shares climbed 8.7% to trade at 27.80 following the simultaneous release of its half-year fiscal 2025/26 results and the unveiling of a broad restructuring program. The market reaction came despite a weak set of first-half numbers, as investors focused on the companys plan to arrest margin decline and recover profitability over the next three years.
For the first six months of the fiscal year, revenue contracted 5.7% to 91 million. Adjusted EBITDA fell sharply as well, with the adjusted EBITDA margin narrowing to 6.1% from 10.7% in the comparable prior-year period. Management attributed the weaker performance to a combination of currency headwinds, softer demand for certain equipment, and pressure in Chinas intraocular lens business.
Despite those headline weaknesses, the company provided a detailed response. CEO Andreas Pecher introduced a "Profit Up" initiative designed to address margin erosion across the entire organization. The program spans all business segments, functions, and sites and targets more than 00 million in annual profit improvements by fiscal 2028/29.
Alongside the restructuring, Carl Zeiss Meditec issued guidance for the full fiscal year, forecasting revenue between .15 billion and .2 billion and an adjusted EBITDA margin of 8% to 10%. Management pointed to potential second-half tailwinds including reduced currency headwinds, Chinas seasonal summer peak in refractive laser procedures, and back-end loading of equipment sales.
The stocks strong outperformance on the day stood in contrast to broader market weakness. The DAX index was down 1.0% to 24,096 points at midday as geopolitical concerns weighed. The company-specific rally reflected market pricing that had already internalized significant operational stress: the shares had lost more than half of their value over the prior 12 months and were trading roughly 32% below their 200-day moving average, with technical indicators showing deep oversold conditions.
Analytically, the rally appears to be a classic relief rebound triggered by a credible, quantified turnaround plan combined with valuation and technical characteristics that made the equity susceptible to a snapback. Managements medium-term targets call for organic revenue growth of at least a mid-single-digit percentage and an adjusted EBITDA margin above 15% by fiscal 2028/29. The company also stated it views a long-term adjusted EBITDA margin range of 16% to 20% as achievable.
Investors appeared to reward the specificity and scale of the recovery blueprint: the 00 million-plus annual profit improvement target gives a tangible metric against which future progress can be measured. However, the initial market reaction does not change the underlying near-term performance indicators reported for the first half, which showed declining top-line and margin metrics.
What management announced
- Launch of the "Profit Up" restructuring program covering all segments, functions, and sites, with a target of more than 00 million in annual profit improvements by fiscal 2028/29.
- Full-year revenue guidance of .15 billion to .2 billion and an adjusted EBITDA margin target of 8% to 10% for the fiscal year.
- Medium-term objectives of at least mid-single-digit organic revenue growth and an adjusted EBITDA margin above 15% by fiscal 2028/29, and a long-term margin ambition in the 16% to 20% range.
Market context
The rally occurred against a falling DAX and amid fragile geopolitical developments, highlighting that the move was driven primarily by company-specific developments rather than broader market strength.